Past electron-positron g-2 experiments yielded sharpest bound on CPT violation for point particles

In our past experiments on a single electron and positron we measured the cyclotron and spin-cyclotron difference frequencies omega_c and omega_a and the ratios a = omega_a/ omega_c at omega_c = 141 Ghz for e^- and e^+ and later, only for e^-, also at 164 Ghz. Here, we do extract from these data, as had not done before, a new and very different figure of merit for violation of CPT symmetry, one similar to the widely recognized impressive limit |m_Kaon - m_Antikaon|/m_Kaon < 10^-18 for the K-mesons composed of two quarks. That expression may be seen as comparing experimental relativistic masses of particle states before and after the C, P, T operations had transformed particle into antiparticle. Such a similar figure of merit for a non-composite and quite different lepton, found by us from our Delta a = a^- - a^+ data, was even smaller, h_bar |omega_a^- - omega_a^+|/2m_0 c^2 = |Delta a| h_bar omega_c/2m_0 c^2) < 3(12) 10^-22.Comment: Improved content, Editorially approved for publication in PRL, LATEX file, 5 pages, no figures, 16

DOMESTIC SUPPORT: ISSUES AND OPTIONS IN THE AGRICULTURAL NEGOTIATIONS

International Relations/Trade,

Self-Excitation and Feedback Cooling of an Isolated Proton

The first one-proton self-excited oscillator (SEO) and one-proton feedback cooling are demonstrated. In a Penning trap with a large magnetic gradient, the SEO frequency is resolved to the high precision needed to detect a one-proton spin flip. This is after undamped magnetron motion is sideband-cooled to a 14 mK theoretical limit, and despite random frequency shifts (larger than those from a spin flip) that take place every time sideband cooling is applied in the gradient. The observations open a possible path towards a million-fold improved comparison of the antiproton and proton magnetic moments

Bispectrum speckle interferometry observations and radiative transfer modelling of the red supergiant NML Cyg: Multiple dust-shell structures evidencing previous superwind phases

(abridged) NML Cyg is a highly evolved OH/IR supergiant and supposed to be among the most luminous supergiants in the galaxy. We present the first diffraction limited 2.13micron observations of NML Cyg with 73mas resolution. The speckle interferograms were obtained with the SAO 6m telescope, image reconstruction is based on the bispectrum speckle interferometry method. Radiative transfer calculations have been carried out to model the spectral energy distribution, our 2.13micron visibility function, and mid-infrared visibility functions. The observed dust shell properties do not appear to be in accordance with single-shell models but seem to require multiple components. Considering previous periods of enhanced mass-loss, various density enhancements in the dust shell were taken into account. An extensive grid of models was calculated for different locations and strenghts of such superwind regions in the dust shell. To match the observations from the optical to the sub-mm domain requires at least two superwind regions embedded in the shell. The best model includes a dust shell with a temperature of 1000K at its inner radius of 6.2Rstar, a close embedded superwind shell extending from 15.5Rstar to 21.7Rstar with amplitude 10 (factor of density enhancement), and a far-out density enhancement at 186Rstar with amplitude 5. The angular diameter of the inner dust-shell rim amounts to 105mas. Within the various parts of the dust shell, 1/r^2 density distributions could be maintained differing only in their amplitude A. The present-day mass-loss rate was determined to be 1.2 10^-4 Msol/yr. The inner embedded superwind shell corresponds to a phase of enhanced mass-loss which began ~59yr ago and lasted for ~18yr, and the outer superwind region to a high mass-loss period which terminated 529yr ago.Comment: 12 pages including 13 PostScript figures, also available from http://www.mpifr-bonn.mpg.de/div/ir-interferometry/publications.html; accepted for publication in Astronomy & Astrophysic

Snow ridglng to increase soil water

Non-Peer Reviewe

Theoretical energies of low-lying states of light helium-like ions

Rigorous quantum electrodynamical calculation is presented for energy levels of the 1^1S, 2^1S, 2^3S, 2^1P_1, and 2^3P_{0,1,2} states of helium-like ions with the nuclear charge Z=3...12. The calculational approach accounts for all relativistic, quantum electrodynamical, and recoil effects up to orders m\alpha^6 and m^2/M\alpha^5, thus advancing the previously reported theory of light helium-like ions by one order in \alpha.Comment: 18 pages, 9 tables, 1 figure, with several misprints correcte

Lecanemab in early Alzheimer\u27s disease

BACKGROUND: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer\u27s disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer\u27s disease. METHODS: We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer\u27s disease (mild cognitive impairment or mild dementia due to Alzheimer\u27s disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing. Participants were randomly assigned in a 1:1 ratio to receive intravenous lecanemab (10 mg per kilogram of body weight every 2 weeks) or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater impairment). Key secondary end points were the change in amyloid burden on PET, the score on the 14-item cognitive subscale of the Alzheimer\u27s Disease Assessment Scale (ADAS-cog14; range, 0 to 90; higher scores indicate greater impairment), the Alzheimer\u27s Disease Composite Score (ADCOMS; range, 0 to 1.97; higher scores indicate greater impairment), and the score on the Alzheimer\u27s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL; range, 0 to 53; lower scores indicate greater impairment). RESULTS: A total of 1795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, -0.45; 95% confidence interval [CI], -0.67 to -0.23; P\u3c0.001). In a substudy involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). Other mean differences between the two groups in the change from baseline favoring lecanemab were as follows: for the ADAS-cog14 score, -1.44 (95% CI, -2.27 to -0.61; P\u3c0.001); for the ADCOMS, -0.050 (95% CI, -0.074 to -0.027; P\u3c0.001); and for the ADCS-MCI-ADL score, 2.0 (95% CI, 1.2 to 2.8; P\u3c0.001). Lecanemab resulted in infusion-related reactions in 26.4% of the participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%. CONCLUSIONS: Lecanemab reduced markers of amyloid in early Alzheimer\u27s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer\u27s disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.)